Kura Oncology, Inc. KURA
Regular-session close
After hours · Nov 20, 4:26 PM ET
- YTD
- -33.49%
- 1 year
- -37.07%
5D -0.51 (-6.63%)
- Market cap
- 634.88M
- Revenue (ttm)
- 77.22M
- EPS (ttm)
- -3.30
- Shares out
- 88.96M
- Forward P/E
- -5.11
- YTD return
- -33.49%
- 1-year return
- -37.07%
- 50-day average
- 11.17
- 200-day average
- 9.82
- Volume
- 1.75M
- Avg volume
- 2.10M
- Open
- 7.24
- Previous close
- 7.35
- Day's range
- 6.89 – 7.37
- 52-week range
- 6.75 – 13.90
- Beta
- 0.43
- Analysts
- Strong Buy
- Price target
- 32.00 (+363.1%)
Key statistics
- Enterprise value
- 537.37M
- Price / sales
- 13.51
- Price / book
- 21.56
- Revenue growth
- 36.50%
- Free cash flow
- -165.88M
- Total cash
- 519.02M
- Total debt
- 24.45M
- Return on equity
- -167.71%
- Short % of float
- 15.48%
Fundamental scorecard
3 of 25 checks passed on KURA’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.84 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.87733 | -0.77 | +0.11 | +12.23% |
| May 12, 2026 | Mar 31, 2026 | -0.88 | -0.83 | +0.05 | +5.68% |
| Mar 5, 2026 | Dec 31, 2025 | -0.72 | -0.92 | -0.20 | -27.78% |
| Nov 4, 2025 | Sep 30, 2025 | -0.57 | -0.85 | -0.28 | -49.12% |
| Aug 7, 2025 | Jun 30, 2025 | 0.15 | -0.75 | -0.90 | -600.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Aug 13, 2026 | Wedbush | main | Outperform | Outperform |
| Jul 28, 2026 | Wedbush | reit | Outperform | Outperform |
| Jun 15, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Apr 14, 2026 | Lake Street | init | — | Buy |
| Mar 24, 2026 | Mizuho | main | Outperform | Outperform |
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kuraoncology.com
News
Kura Oncology, Inc. (KURA) Presents at UBS Global Biopharma Conference 2026 Transcript
Kura Oncology: Refills Drive Komzifti Launch, While Funding Bridge Sets The Pace
Kura Oncology to Participate in Two Investor Conferences in November Reported Earlier: Kura Oncology And Kyowa Kirin To Present Eight Ziftomenib Abstracts At ASH 2026, Highlighting Promising AML Combination Data And Expanded Clinical Potential
Your note
Sign in to keep a note on KURA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAIR TERESA BROPHY | Officer | Sale | Aug 18, 2026 | 195,444 |
| BURROWS FRANCIS J. PH.D. | Officer | Sale | Jan 26, 2026 | 32,424 |
| DOYLE THOMAS JAMES | Officer | Sale | Jan 26, 2026 | 145,667 |
| FORD KATHLEEN | Chief Operating Officer | Sale | May 18, 2026 | 153,560 |
| HASNAIN FAHEEM | Director | Conversion of Exercise of derivative security | Dec 8, 2025 | 23,983 |
| LEONI MOLLIE M.D. | Officer | Sale | Jun 17, 2026 | 182,345 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 11.81% | 10,509,233 | 123.27M | Jun 29, 2026 |
| Montanova Capital LLC | 9.64% | 8,575,422 | 100.59M | Jun 29, 2026 |
| BVF Inc. | 9.49% | 8,445,769 | 99.07M | Jun 29, 2026 |
| State Street Corporation | 5.99% | 5,329,208 | 62.51M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.40% | 3,916,164 | 45.94M | Jun 29, 2026 |
| Armistice Capital, LLC | 4.13% | 3,678,000 | 43.14M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.40% | 3,020,727 | 35.43M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 2,799,338 | 32.84M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.44% | 2,168,959 | 25.44M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 1,026,943 | 12.05M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.04% | 921,604 | 10.81M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.88% | 780,455 | 9.15M | Jul 30, 2026 |
